Plozasiran Injection Placebo

DRUG4 trials

Sponsors

Arrowhead Pharmaceuticals Inc.

Conditions

HypertriglyceridemiaSevere hypertriglyceridemia (SHTG)

Phase 3

Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Plozasiran in Adults with Severe Hypertriglyceridemia (SHASTA-4 Study)

Active, not recruitingCTIS2023-509301-80-00

Arrowhead Pharmaceuticals Inc.Severe hypertriglyceridemia (SHTG)

Start: 2024-11-04Target: 138Updated: 2025-10-24

Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Plozasiran in Adults with Severe Hypertriglyceridemia (SHASTA-3 Study)

Active, not recruitingCTIS2023-509300-14-00

Arrowhead Pharmaceuticals Inc.Severe hypertriglyceridemia (SHTG)

Start: 2024-10-31Target: 169Updated: 2026-01-19

Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Plozasiran in Adults with Hypertriglyceridemia (MUIR-3 Study)

Active, not recruitingCTIS2023-509302-30-00

Arrowhead Pharmaceuticals Inc.Hypertriglyceridemia

Start: 2024-11-04Target: 478Updated: 2026-01-19

Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Plozasiran in Adults with Severe Hypertriglyceridemia at High Risk of Acute Pancreatitis (SHASTA-5 Study)

RecruitingCTIS2024-518206-40-00

Arrowhead Pharmaceuticals Inc.Severe hypertriglyceridemia (SHTG)

Start: 2025-11-03Target: 55Updated: 2026-01-12